ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2258

Time on Patiromer Therapy and Impact on Serum Potassium Levels in Real-World German CKD Patients

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Muenz, Daniel G., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • McCullough, Keith, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Massy, Ziad, Centre Hospitalier Universitaire Ambroise Pare, Mons, Wallonie, Belgium
  • Bieber, Brian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Fliser, Danilo, Universitatsklinikum des Saarlandes und Medizinische Fakultat der Universitat des Saarlandes, Homburg, Saarland, Germany
  • Golden, John, Vifor Fresenius Medical Care Renal Pharma, Munich, Spain
  • Moreno Quinn, Carol Patricia, Vifor Pharma, Glattbrugg, Switzerland
  • Calice-Silva, Viviane, Pro-Kidney Foundation, Joinville, Brazil
  • Ramirez de Arellano, Antonio, Vifor Pharma, Glattbrugg, Switzerland
  • Reichel, Helmut, Nephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany
Background

Hyperkalemia (HK) (serum K>5.0 mEq/L) is a frequent condition in patients with chronic kidney disease (CKD) associated with high morbidity and mortality and it is a common reason for RAASi discontinuation and dose limitation. Patiromer is a non-absorbed, sodium-free, potassium (K) binder that has been shown to chronically reduce serum K in patients with HK, enabling RAASi therapy, which is supported by randomized trial evidence in CKD patients. Data on patiromer use in patients with moderate-to-advanced CKD in the real-world setting in Europe is lacking. We describe time to discontinuation and changes in serum K levels among CKD stage 3-5 patients starting patiromer using 2018-21 data from German participants in CKD Outcomes and Practice Patterns Study (CKDopps).

Methods

Duration of patiromer use was estimated by Kaplan-Meier curve, starting at patiromer initiation and censoring for death, dialysis, transplant, or loss of follow-up. Serum K levels are described as mean/median at the baseline and in ranges of 1-30, 31-90 and 91-180 days during the follow up, restricted to patients remaining on patiromer.

Results

Patiromer use was limited to 34 of 90 clinics. We identified 155 Patiromer users, 131 with K measurements at baseline and 110 with at least one follow-up value. 79% of patiromer users were CKD stage 4/5, v. 28% of non-patiromer users in the sample. A large proportion (95%) of patiromer users stayed on treatment past 1 month, with 53% of surviving users continuing for over a year (Fig 1A). Mean serum K levels decreased after patiromer initiation and remained stable under treatment during follow-up (up to 180 days) (Fig 1B).

Conclusion

Most patients were not observed to discontinue patiromer prior to one year after initiation. Mean levels of serum K were lower after patiromer initiation and remained stable during the follow-up period.

Funding

  • Commercial Support